Log In
Thursday 18th July 2019

New study for flu treatments

19th January 2011

GlaxoSmithKline has started a study testing intravenous zanamivir against Roche's best-selling pill Tamiflu as a treatment for patients hospitalised with influenza.

Intravenous zanamivir is not currently approved for sale in any country, but the British drug maker aims to enrol 462 patients in 20 countries and for a Phase III trial, which will measure the time to clinical response in patients with confirmed flu and take around three years to complete. GSK had previously said it planned to develop an intravenous form of zanamivir to help the sickest patients.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2019